Drug Details
General Information of the Drug (ID: DR1866) | ||||
---|---|---|---|---|
Name |
Nitroglycerin
|
|||
Synonyms |
nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerine; Nitroglycerol; Nitrostat; 55-63-0; Trinitroglycerol; Glycerol trinitrate; Nitro-dur; Minitran; Nitroderm; Nitroglyn; Nitronet; Nitrospan; Tridil; Transderm-nitro; Transderm Nitro; Epinitril; Lenitral; Natispray; Nitrocine; Nitrolan; Nitrolingual; Perlinganit; Susadrin; Sustonit; Trinitrin; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Angiolingual; Cordipatch; Corditrine; Klavikordal; Myoglycerin; Nitroglicerina; Nitroletten; Nitroplast; Nitrorectal; Nitroretard; Nitrostabilin; Nysconitrine; Perglottal; Rectogesic; Temponitrin; Trinitrosan; Adesitrin; Angibid; Angorin; Cardamist; Chitamite; Deponit; Glonoin; Glytrin; Millisrol; Niglycon; Nitrodisc; Nitrogard; Nitroglin; Nitrolowe; Nitromel; Nitromex; Nitromint; Percutol; Suscard; Trinalgon; Triniplas; Trinitrol; Vasoglyn; Myocon; Niglin; Nitora; NitroMist; Gilucor nitro; NitroCor; Soup; Blasting oil; Blasting gelatin; Glyceryl nitrate; Nitro-lent; Nitrozell retard; Transiderm-nitro; propane-1,2,3-triyl trinitrate; Coro-Nitro; Nitro-Span; Nitrine-TDC; Spirit of glonoin; Nitrolingual Spray; Glycerin trinitrate; Nitrogliceryna; Nitronal; Transderm-Nitro TTS; Glyceroltrinitraat; Propanetriol Trinitrate; 1,2,3-Propanetriol, trinitrate; 1,2,3-Propanetriyl nitrate; Glycerol, nitric acid triester; Rectiv; Nitroglycerin, spirits of; Spirit of trinitroglycerin; NG; Rcra waste number P081; SK-106N; Solution glyceryl trinitrate; 1,3-dinitrooxypropan-2-yl nitrate; Spirit of glyceryl trinitrate; 1,2,3-propanetrioltrinitrate; NK-843; Glycerol(trinitrate de); 1,2,3-Propanetriol, 1,2,3-trinitrate; NTG; UNII-G59M7S0WS3; Glycerol Nitric Acid Triester; 1,2,3-Propanetriol trinitrate; Gilustenon; Trinitrolong; Sustak; GTN; NitroBid; G59M7S0WS3; Aldonitrin; Cardiodisco; Colenitral; Discotrine; Glycerylnitrat; Lentonitrina; Nitrobukal; Nitrocerin; Nitrocontin; Nitropatch; Nitropercuten; Nitroperlinit; Nitropront; Nitroprontan; Plastranit; Ratiopharm; TNG; Trinipatch; Angiplex; Angonist; Buccard; Cardabid; Cardinit; Dauxona; Diafusor; DTXSID1021407; Glyceryl; Herwicard; Minitram; Mionitrat; Nitradisc; Nitroard; Nitrobaat; Nitroclyn; Nitrocot; Nitrodyl; Nitrolin; Nitropen; Nitroprol; Nitrorex; Nitrovis; Perganit; Polnitrin; Trinitron; Turicard; Vasolator; Vernies; Willong; Anglix; CHEBI:28787; Herzer; Myovin; Nirmin; Nitrek; Sustac; Nitrol Ointment; Trinitrina Erba; Nitradisc Pad; Nitro-Pflaster; Nitrobid Oint; Nitrong Retard; Niong Retard; Nitro Retard; Aquo-Trimitrosan; Nitro Rorer; Nitromack Retard; Nitromint Retard; Nitronal Aqueous; Nitro-Time; Nitrogard-SR; Mi-Trates; Nitradisc TTS; Nitriderm TTS; Nitro-Par; Top-Nitro; Nitrocine 5; Nitrodyl TTS; Nitromint Aerosol; Nitrong-SR; Deponit 5; Deponit-5; Neos nitro OPT; Nit-Ret; Nitroglycerin-ACC; Transderm-N TTS; Nitro Mack Retard; Nitro-M-Bid; Nitro-Mack Retard; Gepan Nitroglicerin; Nitro Dur TTS; Nitroderm TTS-5; GTN-Pohl; Nitroderm TTS Ext; Nitro-Dur 5; Nitrocontin Continus; Deponit TTS 5; Nitro-Gesanit Retard; Cellegesic; Deponit TTS 10; Nitro-Dur 10; Nitrocap; NitroQuick; NitroQuik; NITRO IV; Glycerintrinitrate; Percutol Oint.; Nitrong parenteral; NitrocapT.D.; Glycerine trinitrate; Nitroglycerin (NG); Corangin Nitrokapseln; Trinitroglicerina Fabra; Anogesic; Glonoinum; Gonitro; Minitro; Nitriderm; Nitroject; Vascana; Buccal; Nitrogliceryna [Polish]; Nitroglycerine [French]; Nitrol (pharmaceutical); Tridil sublin; Trinitrine Simple Laleuf; Nitroglicerina [Italian]; Nitroglicerina [Spanish]; Aquo-trinitrosan; Glycerintrinitrate [Czech]; Glyceroltrinitraat [Dutch]; Trinitrin Tablets; NITROLINGUAL PUMPSPRAY; Nitromist (TN); Minitran (TN); HSDB 30; SDM No. 17; Nitroglycerin in Dextrose 5%; Nitro-bid (TN); Nitro-dur (TN); CCRIS 4089; nitroglycerin ointment; Nitric acid triester of gylcerol; Transderm-nitro (TN); Glycerol(trinitrate de) [French]; Glycerol (trinitrate de) [French]; Glycerol (trinitrate de); EINECS 200-240-8; UN0143; UN1204; UN3064; UN3319; Nitroglycerin [USP:JAN]; RCRA waste no. P081; BRN 1802063; 2,3-dinitrooxypropyl nitrate; Nitrofortin; Nitrolande; Nitrosigma; Reminitrol; Solinitrina; Spirits of Nitroglycerin, (1 to 10%); Corangil; Nitrolar; Nitromed; Sutonit; Myocor; trans-nitro; Glonoine oil; Nitro mack; S.N.G.; 2,3-bis(nitrooxy)propyl nitrate; Glycerol-trinitrat; C01DA02; IMX-150; MQX-503; Nitro-PRN; MED-2002; Diluted nitroglycerin; Nitroglycerin tablets; SK-866; SK-878; UN0144; Nitroglycerin Injection; Spirits of nitroglycerin; Nitroglycerine, spirit of; 1,2,3-trinitrooxypropane; CHEMBL730; EC 200-240-8; Nitroglycerin (JP17/USP); 1,2,3-trinitroglycerin-d5; SCHEMBL15421; 4-01-00-02762 (Beilstein Handbook Reference); UN 0143 (Salt/Mix); UN 0144 (Salt/Mix); UN 1204 (Salt/Mix); BIDD:GT0142; Ex168; Nitroglycerin, liquid, not desensitized [Forbidden]; SDM No. 17 (Salt/Mix); SDM No. 27 (Salt/Mix); 1,2,3-Propanetriol trinatrate; 1,2,3-tris-nitryloxy-propane; GTPL7053; Trinitrate 1,2,3-propanetriol; Nitric acid triester of glycerol; HMS2094M15; ZINC8214625; c0061; AKOS030254238; Nitroglycerin, solution in alcohol with > 5% but not > 10% nitroglycerin; DB00727; Nitroglycerin, liquid, not desensitized; FT-0752897; C07455; D00515; 49060-EP2280014A2; 49060-EP2287168A2; 49060-EP2311823A1; 141831-EP2292593A2; Q162867; SR-01000944510; SR-01000944510-1; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin; Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass; 27906-99-6; Nitroglycerin 100 microg/mL in Acetonitrile. Short expiry date due to chemical nature of component(s); Nitroglycerin mixture with >2% but not >10% nitroglycerin, by mass, desensitized [UN3319] [Flammable solid]; Nitroglycerin, desensitized with not <40% non-volatile water insoluble phlegmatizer, by mass [UN0143] [Explosive 1.1D, Poison]; Nitroglycerin, solution in alcohol, with >1% but not >10% nitroglycerin [UN0144] [Explosive 1.1D]; Nitroglycerin, solution in alcohol, with >1% but not >5% nitroglycerin [UN3064] [Flammable liquid]; Nitroglycerin, solution in alcohol, with not >1% nitroglycerin [UN1204] [Flammable liquid]; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 1 mL, certified reference material; Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 5 x 0.2 mL, certified reference material; Trinitroglycerin solution, 1000 mug/mL in acetonitrile, ampule of 1 mL, certified reference material
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Diabetic foot ulcer [ICD-11: BD54] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C3H5N3O9
|
|||
PubChem CID | ||||
Canonical SMILES |
C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
|
|||
InChI |
1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
|
|||
InChIKey |
SNIOPGDIGTZGOP-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 55-63-0
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Khellin | Ammi visnaga | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
Combination of khellin and nitroglycerin in the treatment of angina pectoris. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Epidermal growth factor receptor (EGFR) | Molecule Info | [1] | |
Soluble guanylate cyclase (GCS) | Molecule Info | [3] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | Calcium signaling pathway | |||
6 | Cytokine-cytokine receptor interaction | |||
7 | HIF-1 signaling pathway | |||
8 | FoxO signaling pathway | |||
9 | Endocytosis | |||
10 | PI3K-Akt signaling pathway | |||
11 | Dorso-ventral axis formation | |||
12 | Focal adhesion | |||
13 | Adherens junction | |||
14 | Gap junction | |||
15 | Regulation of actin cytoskeleton | |||
16 | GnRH signaling pathway | |||
17 | Estrogen signaling pathway | |||
18 | Oxytocin signaling pathway | |||
19 | Epithelial cell signaling in Helicobacter pylori infection | |||
20 | Hepatitis C | |||
21 | Pathways in cancer | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Pancreatic cancer | |||
25 | Endometrial cancer | |||
26 | Glioma | |||
27 | Prostate cancer | |||
28 | Melanoma | |||
29 | Bladder cancer | |||
30 | Non-small cell lung cancer | |||
31 | Central carbon metabolism in cancer | |||
32 | Choline metabolism in cancer | |||
NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
2 | EGFR1 Signaling Pathway | |||
Panther Pathway | Cadherin signaling pathway | Click to Show/Hide | ||
2 | EGF receptor signaling pathway | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Signaling events mediated by PTP1B | |||
3 | Arf6 signaling events | |||
4 | Signaling events mediated by TCPTP | |||
5 | Thromboxane A2 receptor signaling | |||
6 | SHP2 signaling | |||
7 | Regulation of Telomerase | |||
8 | EGF receptor (ErbB1) signaling pathway | |||
9 | EGFR-dependent Endothelin signaling events | |||
10 | Posttranslational regulation of adherens junction stability and dissassembly | |||
11 | Direct p53 effectors | |||
12 | ErbB1 downstream signaling | |||
13 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
14 | E-cadherin signaling in keratinocytes | |||
15 | ErbB receptor signaling network | |||
16 | Internalization of ErbB1 | |||
17 | Stabilization and expansion of the E-cadherin adherens junction | |||
18 | a6b1 and a6b4 Integrin signaling | |||
19 | Syndecan-3-mediated signaling events | |||
Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Click to Show/Hide | ||
2 | SHC1 events in ERBB2 signaling | |||
3 | PLCG1 events in ERBB2 signaling | |||
4 | PIP3 activates AKT signaling | |||
5 | GRB2 events in EGFR signaling | |||
6 | GAB1 signalosome | |||
7 | SHC1 events in EGFR signaling | |||
8 | EGFR downregulation | |||
9 | GRB2 events in ERBB2 signaling | |||
10 | PI3K events in ERBB2 signaling | |||
11 | EGFR Transactivation by Gastrin | |||
12 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
13 | Constitutive Signaling by EGFRvIII | |||
14 | RAF/MAP kinase cascade | |||
WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
2 | Regulation of Actin Cytoskeleton | |||
3 | EGF/EGFR Signaling Pathway | |||
4 | MAPK Signaling Pathway | |||
5 | Focal Adhesion | |||
6 | Aryl Hydrocarbon Receptor Pathway | |||
7 | Extracellular vesicle-mediated signaling in recipient cells | |||
8 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
9 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
10 | Bladder Cancer | |||
11 | Hair Follicle Development: Induction (Part 1 of 3) | |||
12 | Signaling by ERBB4 | |||
13 | Signaling by ERBB2 | |||
14 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
15 | PIP3 activates AKT signaling | |||
16 | Nanoparticle-mediated activation of receptor signaling | |||
17 | Aryl Hydrocarbon Receptor | |||
18 | Spinal Cord Injury | |||
19 | Integrated Pancreatic Cancer Pathway | |||
20 | Gastric cancer network 2 | |||
21 | AGE/RAGE pathway | |||
22 | Signaling Pathways in Glioblastoma | |||
23 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
24 | miR-targeted genes in muscle cell - TarBase | |||
25 | miR-targeted genes in lymphocytes - TarBase | |||
26 | miR-targeted genes in epithelium - TarBase | |||
27 | Integrated Breast Cancer Pathway | |||
28 | Signaling by EGFR | |||
29 | L1CAM interactions |
